DK3169405T3 - Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme - Google Patents
Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme Download PDFInfo
- Publication number
- DK3169405T3 DK3169405T3 DK15822317.2T DK15822317T DK3169405T3 DK 3169405 T3 DK3169405 T3 DK 3169405T3 DK 15822317 T DK15822317 T DK 15822317T DK 3169405 T3 DK3169405 T3 DK 3169405T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- compounds
- treatment
- methods
- musculoskeletal diseases
- Prior art date
Links
- 208000023178 Musculoskeletal disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462026006P | 2014-07-17 | 2014-07-17 | |
US201462053035P | 2014-09-19 | 2014-09-19 | |
PCT/US2015/041020 WO2016011420A1 (en) | 2014-07-17 | 2015-07-17 | Methods, compounds, and compositions for the treatment of musculoskeletal diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3169405T3 true DK3169405T3 (da) | 2024-09-23 |
Family
ID=55079111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15822317.2T DK3169405T3 (da) | 2014-07-17 | 2015-07-17 | Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme |
Country Status (10)
Country | Link |
---|---|
US (1) | US9943509B2 (da) |
EP (1) | EP3169405B1 (da) |
JP (1) | JP2017521390A (da) |
KR (2) | KR20170026368A (da) |
CN (1) | CN107073295A (da) |
AU (1) | AU2015289420B2 (da) |
CA (1) | CA2953064C (da) |
DK (1) | DK3169405T3 (da) |
RU (1) | RU2016152088A (da) |
WO (1) | WO2016011420A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201810837QA (en) | 2016-06-29 | 2018-12-28 | Univ Montreal | Biarylmethyl heterocycles |
US11446285B2 (en) | 2017-06-16 | 2022-09-20 | University Of Southern California | Methods for treating systemic lupus erythematosus |
WO2019027890A1 (en) * | 2017-08-04 | 2019-02-07 | Gaffney Kevin J | METHODS OF TREATING MYELOSUPPRESSION |
EP3946284A1 (en) * | 2019-03-28 | 2022-02-09 | Société des Produits Nestlé S.A. | Novel depside dimeric compounds for skeletal muscle modulation, methods and uses thereof |
KR20230156030A (ko) * | 2021-01-28 | 2023-11-13 | 케퍼시티 바이오 인코포레이티드 | 질환 치료를 위해 미토콘드리아 전환을 자극하는 방법 및 제제 |
WO2022229351A1 (en) * | 2021-04-28 | 2022-11-03 | Graviton Bioscience Bv | Selective inhibitors of rock2 for the treatment of muscular dystrophy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0855392A3 (de) | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
YU78601A (sh) | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
DE10112041A1 (de) | 2001-03-14 | 2002-09-26 | Aventis Pharma Gmbh | p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
TWI406850B (zh) * | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
WO2011005674A1 (en) * | 2009-07-07 | 2011-01-13 | Theravance, Inc. | Dual-acting pyrazole antihypertensive agents |
US8481549B2 (en) | 2010-01-19 | 2013-07-09 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
WO2013078261A1 (en) * | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
EP3935944A1 (en) | 2013-03-15 | 2022-01-12 | University Of Southern California, USC Stevens | Compounds for the treatment of musculoskeletal diseases |
WO2014189634A1 (en) | 2013-04-19 | 2014-11-27 | University Of Iowa Research Foundation | Angiotensins in muscular dystrophy |
-
2015
- 2015-07-17 EP EP15822317.2A patent/EP3169405B1/en active Active
- 2015-07-17 CN CN201580035056.3A patent/CN107073295A/zh active Pending
- 2015-07-17 DK DK15822317.2T patent/DK3169405T3/da active
- 2015-07-17 CA CA2953064A patent/CA2953064C/en active Active
- 2015-07-17 JP JP2016572738A patent/JP2017521390A/ja active Pending
- 2015-07-17 WO PCT/US2015/041020 patent/WO2016011420A1/en active Application Filing
- 2015-07-17 AU AU2015289420A patent/AU2015289420B2/en active Active
- 2015-07-17 KR KR1020167035588A patent/KR20170026368A/ko active Application Filing
- 2015-07-17 KR KR1020237003386A patent/KR102697698B1/ko active IP Right Grant
- 2015-07-17 US US15/318,735 patent/US9943509B2/en active Active
- 2015-07-17 RU RU2016152088A patent/RU2016152088A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3169405B1 (en) | 2024-08-28 |
WO2016011420A1 (en) | 2016-01-21 |
CA2953064A1 (en) | 2016-01-21 |
US20170119748A1 (en) | 2017-05-04 |
EP3169405A4 (en) | 2018-01-24 |
CA2953064C (en) | 2023-06-20 |
NZ727422A (en) | 2023-12-22 |
EP3169405A1 (en) | 2017-05-24 |
US9943509B2 (en) | 2018-04-17 |
AU2015289420B2 (en) | 2021-03-11 |
JP2017521390A (ja) | 2017-08-03 |
RU2016152088A (ru) | 2018-08-21 |
KR20170026368A (ko) | 2017-03-08 |
AU2015289420A1 (en) | 2017-01-12 |
KR20230020584A (ko) | 2023-02-10 |
KR102697698B1 (ko) | 2024-08-21 |
RU2016152088A3 (da) | 2019-02-12 |
CN107073295A (zh) | 2017-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
DK3594238T3 (da) | Antistofsammensætninger til tumorbehandling | |
DK3377516T3 (da) | Sammensætning til behandling af cancer | |
DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
BR112016022976A2 (pt) | Métodos para o tratamento de hcv | |
DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation |